(S)-((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate hydrogensulfate | 1172614-00-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (S)-((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate hydrogensulfate
• 英文别名: solifenacin hydrogensulfate；solifenacin, sulfuric acid salt；solifenacin hydrogen sulfate；[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;sulfuric acid
• CAS: 1172614-00-4
• 化学式: C₂₃H₂₆N₂O₂*H₂O₄S
• 分子量: 460.551
• InChiKey: NOFRRBNAICXSFY-VROPFNGYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.21
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  索非那新 在 硫酸 作用下， 以 异丙醚 为溶剂， 生成 (S)-((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate hydrogensulfate
  参考文献：
  名称：

  [EN] A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS
  [FR] PROCÉDÉ DE PRÉPARATION DE SELS DE SOLIFÉNACINE ET INCLUSION DE CES DERNIERS DANS DES FORMES PHARMACEUTIQUES

  摘要：

  公开号：

  WO2010012459A3

文献信息

• [EN] PROCESS FOR THE PREPARATION OF SOLIFENACIN AND SALTS THEREOF<br/>[FR] PROCÉDÉ D'ÉLABORATION DE SOLIFÉNACINE ET DE SELS DE SOLIFÉNACINE
  申请人：ISOCHEM SA

  公开号：WO2012175119A1

  公开（公告）日：2012-12-27

  The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (R)- quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid to obtain a diasteroisomeric mixture (S,R)-((R)-quinuclidin-3-yl) 1 -phenyl-3,4- dihydroisoquinoline-2(1 H)-carboxylate of formula (IV) which can be resolved and the solifenacin or a pharmaceutically acceptable acid addition salt thereof recovered. The invention also provides the new key intermediate (R)-quinuclidin-3-yl phenethylcarbamate involved in the process. Further the invention provides a method for the transformation of (R)-((R)-quinuclidin-3-yl) 1 -phenyl-3,4- dihydroisoquinoline-2(1 H)-carboxylate into a diasteroisomeric mixture (S,R)-((R)- quinuclidin-3-yl) 1 -phenyl-3,4-dihydroisoquinoline-2(1 H)-carboxylate.

  该发明提供了一种制备索利那辛或其药用可接受的酸盐的新工艺，包括在酸的存在下将(R)-喹诺啉-3-基苯乙基氨甲酸酯与苯甲醛反应，以获得一个对映异构体混合物(S,R)-((R)-喹诺啉-3-基) 1-苯基-3,4-二氢异喹啉-2(1 H)-羧酸酯的公式(IV)，该混合物可以被分离，然后可以回收索利那辛或其药用可接受的酸盐。该发明还提供了参与该工艺的新关键中间体(R)-喹诺啉-3-基苯乙基氨甲酸酯。此外，该发明提供了一种将(R)-((R)-喹诺啉-3-基) 1-苯基-3,4-二氢异喹啉-2(1 H)-羧酸酯转化为一个对映异构体混合物(S,R)-((R)-喹诺啉-3-基) 1-苯基-3,4-二氢异喹啉-2(1 H)-羧酸酯的方法。
• Process for the Preparation of Solifenacin and Salts Thereof
  申请人：Bessa Bellunt Jordi

  公开号：US20140228575A1

  公开（公告）日：2014-08-14

  The invention provides a new process for the preparation of solifenacin or a pharmaceutically acceptable acid addition salt thereof, comprising reacting (R)-quinuclidin-3-yl phenethylcarbamate with benzaldehyde in the presence of an acid to obtain a diasteroisomeric mixture (S,R)—((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate of formula (IV) which can be resolved and the solifenacin or a pharmaceutically acceptable acid addition salt thereof recovered. The invention also provides the new key intermediate (R)-quinuclidin-3-yl phenethylcarbamate involved in the process. Further the invention provides a method for the transformation of (R)—((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate into a diasteroisomeric mixture (S,R)—((R)-quinuclidin-3-yl) 1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate.

  该发明提供了一种制备索利那辛或其药用可接受的酸盐的新工艺，包括在酸的存在下将(R)-喹诺啡啶-3-基苯乙基氨基甲酸酯与苯甲醛反应，以获得一个立体异构混合物(S,R)-((R)-喹诺啡啶-3-基) 1-苯基-3,4-二氢异喹啉-2(1H)-羧酸酯的公式(IV)，该混合物可以被分离，并可回收索利那辛或其药用可接受的酸盐。该发明还提供了参与该工艺的新关键中间体(R)-喹诺啡啶-3-基苯乙基氨基甲酸酯。此外，该发明提供了一种将(R)-((R)-喹诺啡啶-3-基) 1-苯基-3,4-二氢异喹啉-2(1H)-羧酸酯转化为一个立体异构混合物(S,R)-((R)-喹诺啡啶-3-基) 1-苯基-3,4-二氢异喹啉-2(1H)-羧酸酯的方法。
• [EN] A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE SELS DE SOLIFÉNACINE ET INCLUSION DE CES DERNIERS DANS DES FORMES PHARMACEUTIQUES
  申请人：KRKA D D NOVO MESTO

  公开号：WO2010012459A3

  公开（公告）日：2010-08-05